JP2009519232A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519232A5
JP2009519232A5 JP2008542430A JP2008542430A JP2009519232A5 JP 2009519232 A5 JP2009519232 A5 JP 2009519232A5 JP 2008542430 A JP2008542430 A JP 2008542430A JP 2008542430 A JP2008542430 A JP 2008542430A JP 2009519232 A5 JP2009519232 A5 JP 2009519232A5
Authority
JP
Japan
Prior art keywords
expression
macroglobulin
gene
expression level
intraocular pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008542430A
Other languages
English (en)
Japanese (ja)
Other versions
JP5249774B2 (ja
JP2009519232A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/045169 external-priority patent/WO2007062101A2/en
Publication of JP2009519232A publication Critical patent/JP2009519232A/ja
Publication of JP2009519232A5 publication Critical patent/JP2009519232A5/ja
Application granted granted Critical
Publication of JP5249774B2 publication Critical patent/JP5249774B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008542430A 2005-11-22 2006-11-22 眼内圧調節初期遺伝子およびその使用 Expired - Fee Related JP5249774B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73957005P 2005-11-22 2005-11-22
US60/739,570 2005-11-22
PCT/US2006/045169 WO2007062101A2 (en) 2005-11-22 2006-11-22 Intraocular pressure-regulated early genes and uses thereof

Publications (3)

Publication Number Publication Date
JP2009519232A JP2009519232A (ja) 2009-05-14
JP2009519232A5 true JP2009519232A5 (cg-RX-API-DMAC7.html) 2011-09-15
JP5249774B2 JP5249774B2 (ja) 2013-07-31

Family

ID=38067890

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542430A Expired - Fee Related JP5249774B2 (ja) 2005-11-22 2006-11-22 眼内圧調節初期遺伝子およびその使用

Country Status (7)

Country Link
US (1) US8563520B2 (cg-RX-API-DMAC7.html)
EP (1) EP1957986B1 (cg-RX-API-DMAC7.html)
JP (1) JP5249774B2 (cg-RX-API-DMAC7.html)
CN (1) CN101360999B (cg-RX-API-DMAC7.html)
AU (1) AU2006318550A1 (cg-RX-API-DMAC7.html)
CA (1) CA2630668C (cg-RX-API-DMAC7.html)
WO (1) WO2007062101A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0634001Y2 (ja) 1989-02-02 1994-09-07 石川島播磨重工業株式会社 水平対向型幅プレスの金型取付装置
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
US8648169B2 (en) 2006-12-05 2014-02-11 The Royal Institution For The Advancement Of Learning/Mcgill University Methods of use of Trk receptor modulators
WO2010118340A1 (en) * 2009-04-09 2010-10-14 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma
CN102210851A (zh) * 2011-05-31 2011-10-12 中国人民解放军第三军医大学第一附属医院 人αB-晶体蛋白在制备保护视网膜神经节细胞的药物中的应用
US20140228299A1 (en) * 2011-09-20 2014-08-14 National University Corporation Tokyo Medical And Dental University Prophylactic and therapeutic agent for neurological diseases using lipoproteins and prophylactic and therapeutic method for neurological diseases
EP3140422A1 (en) * 2014-05-03 2017-03-15 The Regents of The University of California Methods of identifying biomarkers associated with or causative of the progression of disease, in particular for use in prognosticating primary open angle glaucoma
US20180021404A1 (en) * 2015-02-20 2018-01-25 The Regents Of The University Of California Methods and compositions for treating glaucoma
JP7033840B2 (ja) * 2016-06-17 2022-03-11 ユーロイミューン・メディツィニシェ・ラボルディアグノシュティカ・アクチエンゲゼルシャフト 神経自己免疫疾患の診断
CN106434933A (zh) * 2016-10-11 2017-02-22 青岛大学 Crybb2基因在制备检测先天性白内障制品中的应用
US12606868B2 (en) 2020-02-24 2026-04-21 The Board Of Regents Of The University Of Texas System Molecular biomarkers and targets for Fuchs' endothelial corneal dystrophy and glaucoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
CN2237430Y (zh) * 1995-07-20 1996-10-16 北京市橡胶制品设计研究院 青光眼房水引流盘
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US6482854B1 (en) * 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉a基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
DE602005012812D1 (de) * 2005-06-13 2009-04-02 Primm Srl Heterodimere Peptide mit NGF Aktivität und deren Verwendung zur Behandlung von neurodegenerativen Krankheiten
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
EP1921087A1 (en) 2006-11-10 2008-05-14 Primm S.R.L. Process for the preparation of cyclic peptides

Similar Documents

Publication Publication Date Title
Zhang et al. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Adams et al. Glaucoma-Next Generation Therapeutics: Impossible to Possible: Adams et al.
JP2024069452A (ja) ドライアイの治療用医薬組成物
CA2536912C (en) Combination therapy for the treatment of ocular neovascular disorders
EP2803357B1 (en) Angiogenesis inhibitors
Ranta et al. Barrier analysis of periocular drug delivery to the posterior segment
CA2749537C (en) Il-1 antagonist compositions for corneal nerve regeneration and protection
EP4374873A2 (en) Methods for treating or preventing opthalmological conditions
Bucolo et al. Dopamine-3 receptor modulates intraocular pressure: implications for glaucoma
WO2008154482A2 (en) Sirna compositions and methods of use in treatment of ocular diseases
US20180221339A1 (en) Compositions and methods for treating and diagnosing ocular disorders
Whitlock et al. Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK
Hudson et al. Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists
US20120014970A1 (en) Therapeutic Compositions for Treatment of Corneal Disorders
Ruan et al. Adrenoceptors in the eye–physiological and pathophysiological relevance
US10011837B2 (en) SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
US20140315811A1 (en) Ophthalmic preparations based on pacap (pituitary adenylate cyclase activating polypeptide) which restore the normal visual function in early glaucoma
US10011832B2 (en) SiRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
Adams et al. Recent developments for the treatment of glaucoma
KR102775781B1 (ko) Acta2 억제제를 유효성분으로 포함하는 망막 또는 맥락막 질환 치료용 조성물
JP2008542385A (ja) 神経損傷の抑制
Crowston et al. Prostaglandin FP receptors do not contribute to 24-hour intraocular pressure variation in mice
Chen et al. The biomechanical properties of the cornea of patients with glaucoma treated with anti-glaucoma topical medications
JP2017200928A (ja) siRNAならびに眼の状態の処置および/または予防のための方法および組成物におけるその使用
MXPA06002293A (en) Combination therapy for the treatment of ocular neovascular disorders